Freeline Therapeutics Holdings plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael J. Parini
- Full Time Employees
- 152
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Stevenage Bioscience Catalyst Stevenage United Kingdom SG1 2FX
- IPO Date
- Aug 7, 2020
- CIK
- 0001810031
- Website
- freeline.life
- Similar Companies
- Business
- Freeline Therapeutics Holdings plc, now operating as Spur Therapeutics Limited following its rebranding in May 2024, is a clinical-stage biotechnology company headquartered in Stevenage, United Kingdom, and founded in 2015 that develops transformative adeno-associated virus (AAV) vector-mediated gene therapies targeting chronic debilitating diseases through liver-directed delivery using its proprietary AAVS3 capsid and optimized expression cassettes. The company focuses on rare and more prevalent conditions in the pharmaceutical and healthcare sectors, with core pipeline products including FLT201, an investigational gene therapy encoding an engineered GCase enzyme variant for Gaucher disease Type 1 currently in Phase 1/2 GALILEO-1 trials showing long-term durability and positive clinical data presented at the ESGCT 32nd Annual Congress in July 2025; preclinical programs advancing toward GBA1-linked Parkinson’s disease with positive proof-of-concept data presented in June 2025 and published in May 2025; and earlier candidates such as FLT190 for Fabry disease, FLT180a for hemophilia B, and exploratory efforts in dementia and cardiovascular diseases. Spur Therapeutics operates primarily from the United Kingdom with clinical and research activities extending to Germany and the United States. In late 2023, Syncona Ltd agreed to acquire Freeline Therapeutics Holdings plc in a $28.3 million all-cash transaction completed in Q1 2024, resulting in delisting from Nasdaq, full privatization as a Syncona portfolio company, and up to $15 million in secured convertible debt financing to support FLT201 advancement; this was followed by share cancellations, re-registration from public limited to private limited status on May 9, 2024, cessation of prior significant controls, and recent capital allotments and charge satisfactions through August 2024 to bolster ongoing operations and pipeline progression.
Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to Shareholders
Syncona to Acquire Freeline Therapeutics
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
Freeline to Participate in Upcoming Investor Conferences
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
New Strong Buy Stocks for July 14
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Freeline to Present at 2023 Jefferies Healthcare Conference
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
Freeline to Present at the Stifel Healthcare Conference